February 02, 2021

Pfizer Expects $15 Billion In 2021 Sales From Its COVID-19 Vaccine-Reuters

Sales from the vaccine - on track to be the drugmaker’s top product this year - could top $15 billion if the company signs more supply contracts, it said. Pfizer said it expects there could be a long-lasting need for COVID-19 vaccines, to combat new virus variants that emerge and to “boost” peoples’ waning immune responses. Reuters, 02/02/2021